



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:33
Last Report Issued 01/25/2016 07:54

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4479SP-POS
Patient ID 4479SP-POS
Chain 16000082
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 16000082
Received 01/25/2016 07:29

Sample ID 16000082-001
Matrix Serum or Plasma
Patient Name 4479SP-POS
Patient ID 4479SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

4479SP Tiagabine, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Tiagabine	50	ng/mL	4.0	
Synonym(s): Gabitril®				

The relationship between tiagabine plasma concentrations and the clinical response is not currently understood. However, trough plasma concentrations from 1 - 234 ng/mL were reported in one major controlled clinical study at doses of 30 to 56 mg per day. A diurnal effect on the pharmacokinetics of tiagabine has been noted; mean steady-state trough concentrations were 40% lower in the evening than in the morning.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.